Kratom Advocates Challenge National Media Over Federal Regulation Stance
Washington, Wednesday, 18 November 2026.
Advocacy groups contested a national report on kratom, highlighting that 23 million Americans use the plant while federal regulators intentionally target lab-made synthetic opioids rather than natural botanical leaf products.
Global Kratom Coalition Responds to CBS ‘60 Minutes’ Segment
On November 17, 2026, the Global Kratom Coalition (GKC) issued a formal rebuttal to a November 15, 2026 ‘60 Minutes’ broadcast that the advocacy group argued mischaracterized the botanical supplement kratom [1]. The coalition contended that the segment conflated natural kratom leaf products—consumed by approximately 23 million Americans [1]—with synthetic derivatives, despite clear federal regulatory distinctions. The GKC statement emphasized that federal regulators, including the U.S. Department of Health and Human Services (HHS) under Secretary Robert F. Kennedy Jr., have consistently differentiated between natural botanical kratom and concentrated synthetic opioids like 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl (MGPI) [1][2].
Federal Regulatory Timeline and Policy Nuances
The regulatory timeline underscores the GKC’s position. On July 29, 2025, the U.S. Drug Enforcement Administration (DEA), HHS, and the U.S. Food and Drug Administration (FDA) jointly initiated federal scheduling actions targeting concentrated synthetic 7-OH and related synthetic opioid products while explicitly excluding natural kratom leaf [2]. This intent was reiterated by FDA Commissioner Marty Makary on July 29, 2025, who stated, ‘We’re not targeting the kratom leaf or ground-up kratom. We are targeting the concentrated synthetic byproduct that is an opioid’ [2]. The GKC praised this approach, with Executive Director Matthew Lowe stating, ‘DEA is demonstrating bold, science-driven leadership by taking aim at these rogue synthetic opioid products’ [2].
Synthetic Alkaloid Controls and Enforcement Actions
On August 26, 2026, synthetic compounds MGPI, MGM-15, and MGM-16 were officially placed into Schedule I, with the GKC supporting these controls while advocating for continued access to natural kratom leaf [2]. The DEA subsequently issued revised Notices of Intent on October 14, 2026, updating concentration thresholds for 7-OH and MGPI to 0.1% by weight (1 mg/g or 1 mg/mL) [2]. Enforcement actions have already materialized, including a federal indictment in Oxford, Mississippi, on October 20, 2026, charging two vape-store employees with possessing MGM-15 and MGPI with intent to distribute products such as SMAX Pseudo-DHM Mango Breeze tablets [2].
Public Health Data and Consumer Advocacy
Public health data further complicates the debate. The Centers for Disease Control and Prevention (CDC) reported 5,208 kratom-involved overdose deaths from 2020 to 2024, though the agency emphasized that detection does not equate to causation, with 79% of 233 poison-center fatalities involving multiple substances [1]. Natural kratom leaf’s average annual detection in overdose deaths is roughly 1,042 cases, compared to 480,000 for smoking-related incidents and 54,045 for opioid-involved overdoses [1]. Consumer advocates, such as Melody Woolf, a chronic pain patient who testified before the FDA in July 2025, argued that natural kratom leaf saved her life, stating, ‘It was kratom only, the powdered leaf, that saved my life’ [1]. Similar testimonials from natural kratom consumers like Dijon Evans and Lesley Thomas highlighted the botanical’s role in managing chronic pain and improving quality of life [1].
Criticism of Media and Expert Representation
The GKC’s response also took aim at the media’s portrayal of kratom, particularly the inclusion of addiction psychiatrist Dr. Andrew Kolodny in the ‘60 Minutes’ segment without counterbalancing perspectives from federally funded kratom researchers [1]. The GKC asserted that Dr. Kolodny’s critiques, which included claims that ‘the risks of kratom outweigh the potential benefits,’ were not representative of the broader scientific consensus [1][3]. The coalition’s statement followed a Facebook Reel of the segment, which featured Dr. Kolodny’s remarks and accrued 38,000 views [3].
Ongoing Regulatory and Legal Tensions
As of November 18, 2026, the regulatory framework remains in flux. The revised thresholds for 7-OH and MGPI have not yet taken effect, though the GKC has called for their swift finalization and sustained enforcement [2]. The group also emphasized the need to preserve access to natural kratom leaf, citing its use by millions of Americans and the plant’s potential therapeutic benefits [1]. The dispute reflects broader tensions between federal oversight, state-level regulations, and industry advocacy, with potential implications for product liability litigation and retail supply chains [GPT].